BACKGROUND:
Disease Background. Prostate cancer is the most commonly diagnosed cancer in men, accounting for 28% of all cancers diagnosed this year. One of every six men will develop prostate cancer in his lifetime, and prostate cancer is the second most common cause of cancer-related death in men. There is a significant health disparity in prostate cancer, with African American men being 1.6 times more likely to be diagnosed with prostate cancer and more than twice as likely to die from the disease than Caucasian men.
2010 Projections:
Overview of the Program. Since its inception in 1997, the Prostate Cancer Research Program (PCRP) has funded research targeted toward the program's mission of eliminating suffering and death from prostate cancer. The PCRP has built a multidisciplinary portfolio of innovative basic, translational, and clinical research that complements initiatives sponsored by other federal agencies. Research awards are made using a two-tier review process composed of peer and programmatic reviews. An important element in the PCRP is its partnership with consumer advocates, who, along with scientists and clinicians, participate during both levels of review. Peer review evaluates the scientific merit of the research proposals, and programmatic review determines the relevance of proposals to the PCRP vision and goals. The Integration Panel, comprised of leading clinicians, scientists, and consumers, makes the final funding recommendations and provides guidance on the PCRP's investment strategies.
The success of the PCRP has encouraged Congress to appropriate additional funds each year since FY97, totaling $970 million through FY09. A total of 10,757 proposals have been received by the PCRP, and 2,174 awards have been funded.
FY10 Program.The PCRP was continued through a FY10 congressional appropriation of $80M. The PCRP released program announcements in January - March 2010 for a total of ten award mechanisms. The two tiers of review for all proposals will be completed by October 2010. FY10 award negotiations will begin in November 2010, and all funds will be obligated by September 30, 2011. Please see Program History for more details.
Program Outcomes. The outcomes of PCRP-funded research can be illustrated in part by the number of resultant publications (4,692), abstracts/presentations (6,322), and patents/licensures (316) reported by awardees to date. Details on each award are located under Search Awards. Recent highlighted research is located in the 2009 Annual Report and under Research Highlights and Consumer Highlights. For more information, please contact CDMRP.PublicAffairs@amedd.army.mil.
1 American Cancer Society - Cancer Facts and Figures 2010.
Disease Background. Prostate cancer is the most commonly diagnosed cancer in men, accounting for 28% of all cancers diagnosed this year. One of every six men will develop prostate cancer in his lifetime, and prostate cancer is the second most common cause of cancer-related death in men. There is a significant health disparity in prostate cancer, with African American men being 1.6 times more likely to be diagnosed with prostate cancer and more than twice as likely to die from the disease than Caucasian men.
2010 Projections:
- An estimated 217,730 men will receive a diagnosis of prostate cancer.
- An estimated 32,050 men will die of prostate cancer. 1
Overview of the Program. Since its inception in 1997, the Prostate Cancer Research Program (PCRP) has funded research targeted toward the program's mission of eliminating suffering and death from prostate cancer. The PCRP has built a multidisciplinary portfolio of innovative basic, translational, and clinical research that complements initiatives sponsored by other federal agencies. Research awards are made using a two-tier review process composed of peer and programmatic reviews. An important element in the PCRP is its partnership with consumer advocates, who, along with scientists and clinicians, participate during both levels of review. Peer review evaluates the scientific merit of the research proposals, and programmatic review determines the relevance of proposals to the PCRP vision and goals. The Integration Panel, comprised of leading clinicians, scientists, and consumers, makes the final funding recommendations and provides guidance on the PCRP's investment strategies.
The success of the PCRP has encouraged Congress to appropriate additional funds each year since FY97, totaling $970 million through FY09. A total of 10,757 proposals have been received by the PCRP, and 2,174 awards have been funded.
FY10 Program.The PCRP was continued through a FY10 congressional appropriation of $80M. The PCRP released program announcements in January - March 2010 for a total of ten award mechanisms. The two tiers of review for all proposals will be completed by October 2010. FY10 award negotiations will begin in November 2010, and all funds will be obligated by September 30, 2011. Please see Program History for more details.
Program Outcomes. The outcomes of PCRP-funded research can be illustrated in part by the number of resultant publications (4,692), abstracts/presentations (6,322), and patents/licensures (316) reported by awardees to date. Details on each award are located under Search Awards. Recent highlighted research is located in the 2009 Annual Report and under Research Highlights and Consumer Highlights. For more information, please contact CDMRP.PublicAffairs@amedd.army.mil.
1 American Cancer Society - Cancer Facts and Figures 2010.
